phenox

WallabyPhenox, a global pioneer in stroke healthcare innovation, has announced the publication of PROST in JAMA Neurology.Share this Article WallabyPhenox boldly sets new benchmark in evidence-based medicine with the PROST trial Irvine, CA February 1st , 2024 WallabyPhenox, a global pioneer in stroke healthcare innovation, has announced the publication of PROST in JAMA Neurology. Commenced in 2019, this clinical study marks a significant advancement in the treatment of strokes caused by large vessel occlusion (LVO), a condition contributing to severe … Read More

phenox GmbH nominated among the Top 500 most innovative medium-sized companies in Germany in the pharmaceutical and medical technology sector.Share this Postphenox GmbH nominated among the Top 500 most innovative medium-sized companies in Germany in the pharmaceutical and medical technology sector. The German Association and Consumer Studies (DtV) has listed the Top 500 most innovative medium-sized companies in Germany in the pharmaceutical and medical technology sector using an objective and data-based method. The study is based on “patent performance” in … Read More

The PROST trial was conducted to evaluate the safety and efficacy of phenox’s pRESET Thrombectomy Device, which has recently received 510k Clearance by the FDA for use in the US.Share this Postphenox Inc. a Wallaby Medical Company, announces the presentation of the PROST Clinical Trial at the International Stroke Conference in Dallas. [Irvine, CA] – phenox Inc. a leading medical device company in the Neurovascular industry, announced the presentation of the primary results of The pRESET for Occlusive Stroke Treatment (PROST) Randomized … Read More

The pRESET product family, which has been available in Europe for over 10 years, is now cleared for use in the United States.Share this Postphenox Inc. a Wallaby Medical Company, announces the FDA 510k Clearance of the pRESET® Thrombectomy Device for the treatment of acute ischemic stroke. [Irvine, CA] – phenox Inc., a leading medical device company in the Neurovascular industry, announced today that its pRESET Thrombectomy Device has received FDA clearance for use to treat acute ischemic stroke. The … Read More

Share this PostWallaby/phenox announces global launch of the pEGASUS HPC Stent System —  the first laser-cut, open-cell stent device with antithrombogenic HPC coating technology.   September 7, 2022, Nice, France Wallaby/phenox has announced the successful global launch of their novel pEGASUS HPC stent at the ESMINT 2022 congress in Nice, France. The introduction of the pEGASUS stent enables more patients to benefit from the HPC surface modification in stent-assisted coiling treatments as well as intracranial atherosclerotic diseases (ICAD) and dissections. The … Read More

Share this PostWallaby Expands Distribution Agreement With Japan Lifeline For Neurovascular Products for the Japan Market Wallaby Medical Holding, Inc. (“Wallaby”) is pleased to announce that it has concluded an updated exclusive Japanese distribution agreement with Japan Lifeline Co., Ltd. (“Japan Lifeline”) for the distributorship of 11 neurovascular treatment devices. The agreement is for a period of 10 years, beginning August 2022. The agreement also covers the Avenir® Coil System, which Japan Lifeline launched last year. Japan Lifeline has been … Read More

Share this PostWallaby / phenox announces expansion of their global reach of pRESET thrombectomy devices for acute ischemic stroke with the successful launch of pRESET at Global Stroke Alliance, Brazil. August 17, 2022 Bochum, Germany. Adding to their already extensive global reach, Wallaby / phenox today announced the introduction of the pRESET® mechanical thrombectomy device for the treatment of acute large vessel occlusive (LVO) stroke into Brazil. This latest expansion into the Brazilian market marks a first product launch since … Read More

Share this Post Wallaby Acquires German Neurovascular Leader Phenox to Accelerate Global Expansion Laguna Hills, Shanghai & Bochum, April 21, 2022 – Wallaby Medical (“Wallaby” or the “Company”), a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke, today announced that it has acquired phenox GmbH, including phenox’s femtos GmbH (“femtos”), (together “phenox”), a German-based global innovation and technology leader in the neurovascular space, for a total consideration of approximately EUR 500 million … Read More

The study results prove that the implantation of p64 was highly reliable.Share this Post Largest real-world Flow Diverter study verifies safety and efficacy for phenox’ p64 Flow Modulation Device The authors of the Diversion-p64 study conclude that phenox’ p64 Flow Modulation Device has a high efficacy and demonstrates one of the lowest rates of morbidity-mortality compared to similar studies. The trial represents the largest prospective study on flow diversion to date. With 420 patients enrolled in 26 centres across 10 … Read More

phenox today announced the introduction of the pRESET® 6-50 mechanical thrombectomy device for the treatment of acute large vessel occlusive (LVO) strokeShare this Postphenox announces the expansion of their technology portfolio for acute ischemic stroke with the global launch of the pRESET® 6-50 mechanical thrombectomy device. Adding to their already extensive technology portfolio, phenox today announced the introduction of the pRESET® 6-50 mechanical thrombectomy device for the treatment of acute large vessel occlusive (LVO) stroke. This latest addition makes the … Read More

With a strong team of engineers, the 5×40 pRESET is the latest addition to the phenox ischemic product portfolioShare this Postphenox is pleased to announce the results of a paper exploring the benefit of choosing a longer stentrieverFollowing its acceptance into Frontiers in Neurology, phenox is pleased to announce the results of a paper exploring the benefit of choosing a longer stentriever in mechanical thrombectomy. In the paper by Serna Candel et. al*, the outcomes of pRESET 4×20 were examined … Read More

(photo by Clodagh Dunlop)The chances of getting access to mechanical thrombectomy, Clodagh Dunlop feels, was ‘like winning the lottery’. Clodagh now wants stroke patients across the UK to have equal 24-hour access to the procedure that saved her life.Share this PostConfiguring 24-hour stroke thrombectomy services to save more patient lives“My stroke was so massive that without a thrombectomy I’d have died,” says Clodagh, a police detective from Northern Ireland, who had a stroke in 2015 aged just 35. “I owe … Read More

The state-of-the-art new building measuring 2,400 m2 has now recently been completed and offers enough space for a total of 160 employees.Share this Post phenox expands even further with the opening of a new building at HQ phenox has once again enlarged its commercial space at its headquarters in Bochum. Due to the current Covid situation, the management decided not to have an opening ceremony. On a neighbouring property in the Technology Quarter not far from Bochum University of Applied … Read More

As part of this strategy and in the light of Brexit, phenox has taken the decision to open a UK entity materialising in its new office south of Birmingham.Share this Postphenox GmbH expands with opening of new UK officeDespite a challenging year 2020, phenox GmbH is pursuing its strategic plans in strengthening the footprint in key markets across Europe. As part of this strategy and in the light of Brexit, phenox has taken the decision to open a UK entity … Read More

The ESMINT webinar provides the opportunity to meet experts, who share their experience, practice, and way of thinking regarding everyday challenges in the field of neurointerventions.Share this PostResults of the international Diversion-p64 study: the largest real-world Flow Diverter experience – Recording is available!On Monday, 30 November 2020, ESMINT held their 41st webinar on the results of the world largest prospective, multicentre Flow Diverter Post-Market Clinical Follow-up study to date. This webinar will be moderated by Dr. Demetrius Lopes, with Prof. … Read More

Award of the certificate of appointment as honorary professor: Dr.-Ing. Hermann Monstadt (left) at the ceremony by the Dean of the Faculty of Mechanical Engineering at the Ruhr-University Bochum, Prof. Dr.-Ing. Marcus PetermannShare this PostRuhr-University Bochum awards Honorary Professorship to Dr.-Ing. Hermann MonstadtOn 20.10.2020, the Faculty of Mechanical Engineering awarded Dr.-Ing. Hermann Monstadt the certificate of appointment as Honorary Professor by the Dean Prof. Dr.-Ing. Marcus Petermann, during a small ceremony. The award honours Hermann Monstadt for his many years … Read More

Share this Postphenox will start development of a new implant for treatment of Sidewall Aneurysms soonPositive News for phenox from the German Federal Ministry of Education and Research. A consortium led by phenox prevailed against eighty-three rival project proposals to win a funding competition from the German Federal Ministry of Education and Research (BMBF). This achievement clears the way for phenox to begin development of a new implant for treatment of sidewall aneurysms. The new device will enable filling and sealing … Read More

pRESET LUX: Noble Alloy Coating (NAC) for full visibility under x-rayShare this Articlephenox announces the launch of NEW pRESET 5-40 & pRESET LUX thrombectomy devicesphenox today announced the full European launch of the pRESET 5-40 and pRESET LUX 4-20 thrombectomy devices after receiving CE mark approval last year. The pRESET device is a stentriever which is used for mechanical thrombectomy in patients with acute ischemic stroke, due to large vessel occlusion. Over the past few years, safety and efficacy using … Read More

phenox GmbH has announced the European launch of the new p64 MW Flow Modulation Device. The device received CE mark in January 2020 and is available with the proprietary HPC surface modification, a new technology which could revolutionize patient care in vascular intervention.

On 12-15 February, phenox celebrated its 7th international Kickoff meeting in Athens. The company had the pleasure to welcome numerous new distribution partners due to an increased geographical footprint.

On Dec, 9th, representatives of the two contract partners phenox and Wallaby Medical met in Shanghai to finalize a strategic partnership. The cooperation focuses on the sale of Wallaby Medical’s Avenir Embolic Coil System for the treatment of brain aneurysms. The system is approved in the CE and FDA markets and is already marketed by phenox in the USA.

phenox is pleased to announce that it has signed an exclusive distribution agreement with Wallaby Medical Inc. for commercialization of The Avenir™ Detachable Coil System in the U.S. and EU markets. The intended use for the Avenir Coil System is for endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae. The Avenir Coil System is also intended for arterial and venous embolization in the peripheral vasculature.

“The Avenir Coil is highly complementary to our existing portfolio of neurovascular technologies, and we are looking forward to our commercial partnership with Wallaby Medical” said James Lago, CEO of phenox Inc. and General Manager, International of phenox GmbH.

The Avenir Coil System offers a full line of coils including exceptional stable framing coils, extra volume filling coils and ultra-soft finishing coils. Avenir has a streamlined and intuitive, integrated mechanical detachment mechanism with no handle or external energy source required.

About phenox
Founded in 2005, phenox is a privately held company that develops and manufactures innovative treatment options for both hemorrhagic and acute ischemic stroke. phenox has operations in Germany, Ireland, and the United States.

About Wallaby Medical
Wallaby Medical, Inc. is a private company located in Laguna Hills, California that focusses on developing products for treating hemorrhagic and ischemic stroke.

Contact Information:
info@phenox.com

Named the queen of Belgrade by EBSA.tv, Diana Stateczny became Europe’s 2019 snooker champion. Her 24 years of training at the table with a decade dedicated to snooker paid off.
Her victory is impressive. She doesn’t train like the others, she works full time on top of training. To a certain extent, she admits her work is part of her training and it contributed to make her the person she is today: down to earth, focused and dynamic.
“When I go play snooker after a working day behind the microscope, I have learned how to stay present, focused, and work on my endurance. My job also helped me become a more flexible person. When I went to Ireland for a few weeks, I did not train at all. On my return, I realized how grateful I was to play snooker again and this break brought me a lot.”
Discrete, calm yet ambitious, Diana is a confident women who constantly seeks to grow both at work and in snooker. When she works, she is concentrated, disciplined and precise, the same way she plays.
“phenox is proud to have Diana on the team and we are thrilled about her great victory”, says Dr.-Ing. Hermann Monstadt, managing partner at phenox.

The „AntiThromb“ project is announced to be the winner of the KMU-NetC competition of the Federal Ministry of Education and Researsch and therefore receives an enormous funding out of federal resources. The goal of the phenox project is to develop a path-breaking coating, which imitates the natural vessel wall, to be used on implants for the treatment of cerebral aneurysms. The use of such a coating it would make it possible to reduce lifelong medication which still is the current standard.Such a medication is necessary to prevent the formation of a thrombus caused by the use of implants in the cerebral artery and therefore presents the standardized procedure. „For patients where medications do not take effect or are not favorable for other clinical reasons, coated implants could be a promising alternative.” says phenox CEO and managing partner Dr.-Ing. Hermann Monstadt. The challenges of developing such a technology consist in the processing of innovative combinations of raw material, the specialized coating technology as well as the production of the filigree implant structures. Through surface coating the implant is made almost “invisible” to the human immune system to prevent any kind of thromboembolic reactions.The overall volume of the „AntiThromb“ funding project comprises of 2.1 million Euro and is planned to be ongoing for 24 months. Apart of phenox GmbH, being in the production of medical products for the treatment of neurovascular strokes for more than 10 years, other Bochum located companies take part as well. Those are femtos GmbH, a start-up company specialized on miniaturized laser polishing procedure, the department for engineering of Ruhr-University Bochum, Knappschaftschaftskrankenhaus Bochum Hospital as well as the Leibniz Institute of Analytical Sciences –ISAS – e.V. Dortmund and OxProtext GmbH located in Münster. The project is coordinated by NanoMikroWerkstoffPhotonik.NRW Cluster.The support measure „„KMU-NetC“ of the 10-point-programm „priority for the middle class“ the Federal Ministry for Education and Science supports small and medium sized companies in regional networks and clusters. These companies are especially challenged by continuously renewing their processes, products, services and business models in terms of opening up new market potentials. A helpful factor is the association with other companies, universities or research institutes, who have already been successful at developing similar innovation strategies. Experiences and competences are being shared which alleviates and accelerates innovation in the mid-sized sector.